Evidence map›Paper›PMID 34782734›Full record

ArticleCommunications biology2021

Author Correction: Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action.

Rachel L Palte, Veronica Juan, Yacob Gomez-Llorente, Marc Andre Bailly, Kalyan Chakravarthy, Xun Chen, Daniel Cipriano, Ghassan N Fayad, Laurence Fayadat-Dilman, Symon Gathiaka and 15 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Rachel L PalteDepartment of Discovery Chemistry, Merck & Co., Inc., Boston, MA, USA. rachel.kubiak@merck.com.ORCID http://orcid.org/0000-0001-6146-0551
Veronica JuanDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Yacob Gomez-LlorenteDepartment of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
Marc Andre BaillyDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Kalyan ChakravarthyDepartment of Discovery Biology, Merck & Co., Inc., Boston, MA, USA.
Xun ChenDepartment of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
Daniel CiprianoDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Ghassan N FayadDepartment of Preclinical Development, Merck & Co., Inc., Boston, MA, USA.
Laurence Fayadat-DilmanDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Symon GathiakaDepartment of Discovery Chemistry, Merck & Co., Inc., Boston, MA, USA.
Heiko GrebDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Brian HallDepartment of Discovery Biologics, Merck & Co., Inc., Boston, MA, USA.
Mas HandaDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Mark HsiehDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Esther KofmanDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Heping LinDepartment of Discovery Biologics, Merck & Co., Inc., Boston, MA, USA.
J Richard MillerDepartment of Discovery Biology, Merck & Co., Inc., Boston, MA, USA.
Nhung NguyenDepartment of Discovery Biologics, Merck & Co., Inc., South San Francisco, CA, USA.
Jennifer O'NeilDepartment of Discovery Oncology, Merck & Co., Inc., Boston, MA, USA.
Hussam ShaheenDepartment of Discovery Biologics, Merck & Co., Inc., Boston, MA, USA.
Eric SternerDepartment of Discovery Biologics, Merck & Co., Inc., Boston, MA, USA.
Corey StricklandDepartment of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.
Angie SunDepartment of Discovery Biologics, Merck & Co., Inc., Boston, MA, USA.
Shane TaremiDepartment of Discovery Biologics, Merck & Co., Inc., Boston, MA, USA.
Giovanna ScapinDepartment of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34782734
PMCPMC8593008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.